EARSS: European Antimicrobial Resistance Surveillance System; data from the Netherlands (1999).Incidence and resistance rates for Streptococcus pneumoniae and Staphylococcus aureus

Abstract

Gevoeligheid voor antimicrobiele middelen in Streptococcus pneumoniae en Staphylococcus aureus werd bepaald in 1999 in Nederland binnen het raamwerk van het European antomicrobial Resistance Surveillance System (EARSS). Het EARSS project had in Nederland een dekkingsgraad van 40% van de Nederlandse populatie (extramuraal) en 40% van het totale aantal patientdagen (intramuraal). Resistentiie tegen penicilline in S. pneumoniae was minimaal; slechts 9 van 767 (1,2%) isolatn waren niet gevoelig. Resistentie tegen oxacilline in S. aureus was ook laag; slechts 4 ((0,3%) isolaten waren MRSA. de incidentie van invasieve S. pneumoniae was 117 gevallen/1.000.000 persoonsjaren, de incidentie van invasieve penicilline niet gevoelige S. pneumoniae was 1 geval/1.000.000 persoonsjaren. De incidentie van invasieve S. aureus infecties was 0,25 gevallen/1000 patientdagen; de incidentie van invasieve MRSA infecties was 0,0006 gevallen/1000 patientdagen. hetis duidelijkj dat resistentie tegen antibiotica bij deze twee pathogenen in vergelijkijng tot andere Europese landen nog steeds erg laag is.<br>

In a porspective prevalence and incidence survey in The Netherlands in 1999 antimicrobial susceptibility data on invasive Streptococcus pneumoniae and Staphylococcus aureus infections were collected sithin the framework of European Antomicrobial Resistance Surveillance System (EARSS). The EARSS project covered approximately 40% of the Dutch population (extramural) and 40% of the total number of patient-days (intramural). Penicillin resistance in S. pneumoniae was minimal; only 9 of 767 (1,2%) isolates were non-susceptible. Resistance to oxacillin in S. aureus was low, only (0,3%) isolates were MRSA (mecA positive). The incidence of invasive S. pneumoniae was 117 cases/1.000.000 person-years; the incidence of invasive penicillin non-susceptible S. pneumoniae was 1 case/1.000.000 person-years. The incidence of invasive S. aureus infections was 0.25 cases/1000 patient-days; the incidence of invasive MRSA infections was 0.0006 cases/1000 patient-days. It may be concluded that resistance to antibiotics in these two pathogens, when compared to other European countries, is still very low.<br>